Lipiodol retention pattern predicts transarterial chemoembolization therapeutic effect in hepatocellular carcinoma
Main Article Content
Abstract
Article Details
Issue
Section
The journal allows the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
How to Cite
References
Altekruse S, McGlynn K, Reichman M.
Hepatocellular carcinoma incidence, mortality,
and survival trends in the United States from
to 2005. J Clin Oncol 2009;27:1485-91.
Siegel R, Naishadham D, Jemal A. Cancer
statistics 2013. CA Cancer J Clin 2013;63:11-
Venook AP, Papandreou C, Furuse J, et al. The
incidence and epidemiology of hepatocellular
carcinoma: a global and regional perspective.
Oncologist 2010;15 Suppl 4:S5-13.
Gomaa AI, Khan SA, Toledano MB, et al.
Hepatocellular carcinoma: epidemiology, risk
factors and pathogenesis. World J Gastroenterol
;21;14:4300-8.
Parkin DM, Bray F, Ferlay J, et al. Global cancer
statistics, 2002. CA Cancer J Clin 2005;55:74-
Ferlay J, Shin HR, Bray F, et al. Estimates of
worldwide burden of cancer in 2008:
GLOBOCAN 2008. Int J Cancer 2010;127:
-917.
Gani RA. Faktor risiko dan mekanisme
karsinogenesis hepatoma. Semarang:
Gastroenterohepatology Update II Clinical
application in Gastroenterohepatology;2012.
Marrero J. Current treatment approaches in
HCC. Clin Adv Hematol Oncol 2013;11 Suppl
:S15-8.
Adam A, Mueller PR. Interventional radiological
treatment of liver tumors. New York: Cambridge
University Press;2009.
Kawaguchi T, Ohkawa K, Imanaka K, et al.
Lipiodol accumulation and transarterial chemo
embolization efficacy for HCC patients.
Hepatogastroenterol 2012;59:219-23.
Lo CM, Ngan H, Tso WK, et al. Randomized
controlled trial of transarterial lipiodol
chemoembolization for unresectable
hepatocellular carcinoma. Hepatol 2002;35:
-71.
Kasai K, Ushio A, Kasai Y, et al. Therapeutic
efficacy of transarterial chemo-embolization with
a fine-powder formulation of cisplatin for
hepatocellular carcinoma. World J Gastroenterol
;19:2242-8.
Takayasu K, Arii S, Ikai I, et al. Prospective
cohort study of transarterial chemoembolization
for unresectable hepatocellular carcinoma in
patients. Gastroenterol 2006;131:461-9.
Cruite I, Tang A, Sirlin CB. Imaging-based
diagnostic systems for hepatocellular carcinoma.
Am J Roentgenol 2013;201:41-55.
Bialecki ES, Bisceglie AM. Diagnosis of
hepatocellular carcinoma. HPB 2005;7:26-34.
Pentecost M. Interventional therapies for hepatic
malignancy. In: Baum S, Pentecost M, editors.
Abram’s angiography interventional radiology.
Philadelphia: Lippinott Wiliams & Wikins;2006.
p.516-24.
Shin WS. The current practice of transarterial
chemoembolization for the treatment of
hepatocellular carcinoma. Korean J Radiol 2009;
:425-34.
Cheng HY, Xu AM, Chen D, et al. Adjustment
of lipiodol dose according to tumor blood supply
during the transcatheter arterial
chemoembolization for large hepatic carcinoma
by multidetector helical CT. Chinese J Oncol
;25:186-9.
Lim HS, Jeong YY, Kang HK, et al. Imaging
features of hepatocellular carcinoma after
transcatheter arterial chemoembolization and
radiofrequency ablation. Am J Roentgenol 2006;
:341-9.
Matsuo N, Uchida H, Sakaguchi H, et al. Optimal
lipiodol volume in transcatheter arterial
chemoembolotherapy for hepatocellular
carcinoma: study based on lipiodol accumulation
patterns and histopathologic findings. Semin
Oncol 1997;24 Suppl 6:S67-70.
Llovlet JM, Ducreux M, Lencioni R, et al.
EASL—EORTC clinical practice guidelines:
management of hepatocellular carcinoma. J
Hepatol 2012;56: 908-43.
Talwalkar JA, Gores GJ. Diagnosis and staging
of hepatocellular carcinoma. Gastroenterol
;127 Suppl 1:S126-32.
Omata M, Lesmana LA, Tateishi R, et al. Asian
Pacific Association for the Study of the Liver
consensus recommendations on hepatocellular
carcinoma. Hepatol Int 2010;4:439-74.
Jelic S, Sotiropoulos GC. Hepatocellular
carcinoma: ESMO clinical practice guidelines
for diagnosis, treatment and follow-up. Ann
Oncol 2010;21 Suppl 5:S59-64.
Zhang JW, Feng XY, Liu HQ, et al. CT volume
measurement for prognostic evaluation of
unresectable hepatocellular carcinoma after
TACE. World J Gastroenterol 2010;16:2038-45.
Prasad SR, Jhaveri KS, Saini S, et al. CT tumor
measurement for therapeutic response
assessment: comparison of unidimensional,
bidimensional, and volumetric techniques initial
observations. Radiol 2002;225:416-9.
Guan YS, Hu Y, Liu Y. Multidetector-row
computed tomography in the management of
hepatocellular carcinoma with transcatheter
arterial chemoembolization. J Gastroenterol
Hepatol 2006;21:941-6.